WIS Workplace Impairment Solutions Toronto
 
Evidence on Acute & Residual Neurocognitive Effects of Cannabis Use in Adolescents & Adults: Systematic Metareview of Meta-analyses

Evidence on Acute & Residual Neurocognitive Effects of Cannabis Use in Adolescents & Adults: Systematic Metareview of Meta-analyses

WIS has highlighted key points in this article.
ADDICTION SSA
(Nov. 2021)
 
Imperfect Science of Cannabis Impairment Testing

Imperfect Science of Cannabis Impairment Testing

WIS has highlighted key points in this article.
By John Gilmore THE LAWYER'S DAILY
(Feb. 14 / 2019)
 
Employers face a serious challenge in cannabis testing in the workplace — the current science cannot test for present impairment. Cannabis has unique qualities that make it unlike other drugs or alcohol. It is processed differently by the body, creates inactive byproducts and is retained in body tissue for weeks or longer.

Problems With Laboratory Only Determination of Impairment

Problems With Laboratory Only Determination of Impairment

WIS has highlighted key points in this article.
By Esther Carenza THE LAWYER'S DAILY
(Mar. 28 / 2019)
 
The institutions responsible for toxicological analysis of biological samples are imperative for the fair trial of cases involving allegations of driving while impaired by drugs. However, while they can be conclusive on whether a drug was detected, they will not have the ability to determine the timelines of a person’s drug impairment.

Cannabis Impairment Far Different From Alcohol Impairment

Cannabis Impairment Far Different From Alcohol Impairment

WIS has highlighted key points in this article.
By Nathan Baker THE LAWYER'S DAILY
(June 18, 2018)
 
The amendments to the Criminal Code through Bill C-46 are far reaching and significant. Originally, the intention was to pass this law in concert with the Cannabis Act to create new driving offences at the same time that marijuana was legalized. However, it appears that this bill is unlikely to come into force until well after the Cannabis Act is passed.

Issues When Measuring Drug Toxicity

Issues When Measuring Drug Toxicity

WIS has highlighted key points in this article.
By Esteher Carenza THE LAWYER'S DAILY
(Mar.19 / 2019)
 
This column is the corollary to my earlier story: Problems with measuring drug toxicity. An important issue which arises from the biological samples taken by a drug recognition expert (DRE) involves s. 254(3.4(a)(b) and (3.6) of the Criminal Code where they read as follows:

 
Webcraft, Maintenance & Hosting
Custom Websites Canada